-
EP4011898
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4011898
| EP4011898 - 3-HYDROXY-5-PREGNANE-20-ONE DERIVATIVE AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 13.05.2022 Database last updated on 31.08.2024 | |
| Former | The international publication has been made Status updated on 19.02.2021 | Most recent event Tooltip | 27.08.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Gerbera Therapeutics, Inc. 592 Apollo Street Brea, CA 92821 / US | [2022/24] | Inventor(s) | 01 /
LIU, Fei 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 02 /
WU, Gang 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 03 /
LIN, Chenggang 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 04 /
WANG, Xiaobo 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 05 /
WANG, Xiaoqiang 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 06 /
WANG, Ruzhi 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 07 /
ZHU, Bin 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 08 /
XU, Kongchao 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 09 /
SUN, Xiaoyan 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 10 /
CAI, Jun 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 11 /
WANG, Lin 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 12 /
JIANG, Weihua 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | 13 /
ZHENG, Minqiang 539, Building F6, 9 Weidi Road, Qixia District Nanjing, Jiangsu 210046 / CN | [2022/24] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2022/24] | Application number, filing date | 20852240.9 | 07.08.2020 | [2022/24] | WO2020CN107965 | Priority number, date | CN201910736020 | 09.08.2019 Original published format: CN201910736020 | [2022/24] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021027744 | Date: | 18.02.2021 | Language: | ZH | [2021/07] | Type: | A1 Application with search report | No.: | EP4011898 | Date: | 15.06.2022 | Language: | EN | [2022/24] | Search report(s) | International search report - published on: | CN | 18.02.2021 | (Supplementary) European search report - dispatched on: | EP | 22.08.2023 | Classification | IPC: | A61K31/57, A61K31/58, A61P25/00, A61P25/22, A61P25/24, A61P25/20, A61P25/28, A61P25/18, A61P25/08, A61P25/16, A61P25/14, A61P25/30, C07J41/00, C07J43/00 | [2023/38] | CPC: |
A61P25/00 (EP,CN);
C07J7/002 (CN,US);
A61P25/08 (EP,CN);
A61P25/14 (EP,CN);
A61P25/16 (EP,CN);
A61P25/18 (EP,CN);
A61P25/20 (EP,CN);
A61P25/22 (EP,CN);
A61P25/24 (EP,CN);
A61P25/28 (EP,CN);
A61P25/30 (EP,CN);
C07J41/005 (EP);
|
| Former IPC [2022/24] | C07J7/00, A61K31/57, A61K31/58, A61P25/00, A61P25/22, A61P25/24, A61P25/20, A61P25/28, A61P25/18, A61P25/08, A61P25/16, A61P25/14, A61P25/30 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/24] | Title | German: | 2-HYDROXY-5-PREGNAN-20-ON-DERIVATE UND VERWENDUNG DAVON | [2022/24] | English: | 3-HYDROXY-5-PREGNANE-20-ONE DERIVATIVE AND USE THEREOF | [2022/24] | French: | DÉRIVÉ DE 3-HYDROXY-5-PREGNANE-20-ONE ET SON UTILISATION | [2022/24] | Entry into regional phase | 15.02.2022 | Translation filed | 15.02.2022 | National basic fee paid | 15.02.2022 | Search fee paid | 15.02.2022 | Designation fee(s) paid | 15.02.2022 | Examination fee paid | Examination procedure | 15.02.2022 | Examination requested [2022/24] | 18.03.2024 | Amendment by applicant (claims and/or description) | 18.03.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 25.08.2022 | Renewal fee patent year 03 | 25.08.2023 | Renewal fee patent year 04 | 27.08.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO9303732 (COCENSYS INC [US]) [Y] 1-10 * example 6 * * page 45; table 2 * * page 48; table 3 *; | [Y]WO9521617 (COCENSYS INC [US]) [Y] 1-10 * page 99; table 11 *; | [Y]WO2006110172 (HOLLIS EDEN PHARMACEUTICALS [US]) [Y] 1-10* pages 39-40, paragraphs 102-103 *; | [Y]WO2009120565 (UNIV MARYLAND [US], et al) [Y] 1-10 * claim 10; compound 5. 6 * * page 13, paragraph 3 * * page 2, paragraph l - page 3, paragraph 1 *; | [Y]WO2019108673 (VIEWPOINT THERAPEUTICS INC [US]) [Y] 1-10 * page 40; compounds 1.1, 1.2, 1.3a, 1.3b * * examples 9-12 * * page 11, paragraphs 34-35 * |